Peptide Synthesis Market Analysis by Product (Equipment, Reagents & Consumables, and Other); by Technology (Solid-Phase, Liquid-Phase, and Hybrid and Recombinant); and by End User {Pharmaceutical & Biotechnology Companies, Contract Development and Manufacturing Organization (CDMO), and Research Institutes} – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035
Buy Now Report ID: 4800 | Published Date: Apr 08, 2023
The global peptide synthesis market size is estimated to reach ~USD 5 Billion by the end of 2035 by growing at a CAGR of ~10.20% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of peptide synthesis was ~USD 2 Billion. The growth of the market can be attributed to the rising demand for personalized medicine and the increasing adoption of precision medicine. The development of personalised medicines allows doctors to tailor treatments to each individual patient’s specific needs and characteristics. This allows for more accurate diagnosis and more effective treatments, with fewer side effects and better outcomes. Currently, there are more than 300-310 personalized medicines available for people suffering from cancer, genetic disorders, and chronic or infectious diseases. Peptides are increasingly being used as therapeutic agents in precision medicine owing to their ability to precisely target disease-causing molecules. With the growing investment in precision medicine research and development, the demand for peptide synthesis is expected to increase significantly.
In addition to these, factors that are believed to fuel the market growth of peptide synthesis include the increasing focus on protein-based therapeutics, rising investments in the development of peptide-based drugs, increasing prevalence of Cardiovascular Diseases (CVDs), and growing awareness regarding the benefits of peptides in research and clinical applications. Approximately 17.9 million deaths occur per year as a result of cardiovascular diseases (CVDs), according to the World Health Organization (WHO). According to the Centers for Disease Control and Prevention, approximately 697,000 Americans died from heart disease in 2020. Peptides are used to treat these conditions and are also used as a potential replacement for traditional drugs owing to their high efficacy and increased safety. This is predicted to present the potential for market expansion over the projected period.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~10.20% |
|
Base Year Market Size (2022) |
~ USD 2 Billion |
|
Forecast Year Market Size (2035) |
~ USD 5 Billion |
|
Regional Scope |
|
Growth Drivers
Increasing Use of Peptides in Pharmaceutical Drugs Along with A Rise in FDA Approval - Peptides provide a number of advantages over traditional drug substances. They have fewer side effects, are more quickly absorbed into the body and can target specific areas of the body. Furthermore, they are more cost effective to manufacture and are more stable than traditional drug substances, making them a preferred choice for many pharmaceutical drugs. In addition, the FDA has approved eight peptides, two oligonucleotides, and two ADCs that contain peptides out of fifty drugs that were submitted to the FDA in 2021.
Expanded Use of Peptides for Treating COVID-19- According to research published in August 2022, more than 100 peptide drugs were under development to treat COVID-19. It includes 15 synthetic peptides for acute respiratory distress syndrome (ARDS), as well as other respiratory illnesses caused by SARS-Cov-2. Peptides are naturally produced by the human body and have the potential to be developed into effective therapies owing to their ability to target specific receptors in the body. As a result, they have become a promising avenue for drug development for the treatment of COVID-19.
Rising R&D Spending by The Pharmaceutical Sector Along with Rise in Drug Approvals- For instance, 83 billion dollars were spent on R&D by the pharmaceutical industry in 2019 in the United States. The number of new drugs approved for sale between 2010 and 2019 increased by 60% as compared to the previous decade, reaching 59 in 2018.
Rising Cancer Prevalence Worldwide - As per the American Cancer Society Journal, in 2020, men had a 19% higher cancer incidence rate (222.0 per 100,000) than women (186 per 100,000). WHO also reports that cancer is a leading cause of death globally, with nearly ten million deaths in 2020. Peptides have been used in the treatment of various types of cancers and have shown promising results. The rising demand for better treatments and therapies for cancer is expected to drive the peptide synthesis market in the coming years.
Development and Approval of Novel Peptides for Obesity and Weight Maintenance - According to the United States Food and Drug Administration (US FDA), Imcivree (setmelanotide), a pro-opiomelanocortin-derived peptide, was approved for chronic weight management (loss and maintenance of weight for at least a year) for obese patients with rare genetic conditions aged six years and older.
Challenges
The global peptide synthesis market is segmented and analyzed for demand and supply by product into equipment, reagents & consumables, and other. Out of these, the reagents & consumables segment is estimated to gain the largest market share of about ~37% in the year 2035. This segment consists of both organic and inorganic reagents, which are used in the synthesis of different types of peptides. Moreover, the rising demand for peptides in research and drug discovery activities is driving the segment's growth. For instance, there are currently 6020 entries in the HORDB database, including 5720 peptide hormones and 42 peptide drugs, as a result of a study on peptide hormones. Additionally, the rising need for novel and cost-effective reagents and consumables for peptide synthesis is driving the growth of the segment.
Further, by the end of 2035, the equipment sub segment is estimated to hold a significant share of the peptide synthesis market. the growth of the segment can be attribute to the increasing demand for automated systems, which makes the equipment segment more attractive to researchers and manufacturers. Furthermore, the need for faster and more efficient peptide synthesis is driving the need for advanced equipment. The advanced equipment offers increased speed and efficiency of the peptide synthesis process, which is crucial in order to meet the ever-increasing demand of peptides in the market.
The global peptide synthesis market is segmented and analyzed for demand and supply by end user into pharmaceutical & biotechnology companies, contract development and manufacturing organization (CDMO), and research institutes. Out of these, the pharmaceutical & biotechnology companies segment is estimated to gain the significant market share of about ~35% in the year 2035. The growth of the segment can be attributed to the rapid growth of pharmaceutical and biotechnology companies, the rising number of biologics, and the increasing awareness of peptide synthesis technology. It is estimated that the Indian pharmaceutical industry is worth USD 40 billion worldwide. A 17% increase in the Indian pharmaceutical sector was recorded in August 2021, up from a 13% increase in July 2020. The increasing number of pharmaceutical and biotechnology companies has resulted in an increased demand for peptide synthesis technology, which has led to the development of more advanced peptide synthesis products. Additionally, the rising number of biologics has created a need for more efficient peptide synthesis methods, and the increasing awareness of peptide synthesis technology has enabled companies to capitalize on the market potential. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global peptide synthesis market includes the following segments:
|
By Product |
|
|
By Technology |
|
|
By End User |
|
The market share of peptide synthesis in North America, among the market in all the other regions, is projected to be the largest with a share of about ~35% by the end of 2035. The growth of the market can be attributed primarily to the growing number of initiatives taken by the government and research institutes to develop novel peptide-based therapeutic drugs. Additionally, the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases has increased the demand for peptide-based drugs, which is propelling the growth of the peptide synthesis market in North America. For instance, a recent report by the International Diabetic Federation (IDF) indicates that an estimated 51 million adults aged 20-29 years in the North America Caribbean (NAC) region were living with diabetes in 2021, which represents a 14.6% regional prevalence. It is estimated that 193,000 children and adolescents in the region have type 1 diabetes. As the prevalence of diabetes increases, so does the need for insulin and other drugs that are made using peptide synthesis. Many drugs used to treat diabetes and its associated symptoms are made up of peptides, which can only be produced through peptide synthesis, and this is anticipated to contribute to the market growth of the region.
The Asia Pacific peptide synthesis market is estimated to be the second largest, registering a share of about ~24% by the end of 2035. The growth of the market can be attributed majorly to the growing prevalence of chronic diseases, increasing demand for peptide-based drugs, and technological advancements in peptide synthesis. Peptides are a key component of many treatments for chronic diseases, such as diabetes, cancer, and neurological disorders, making them an increasingly significant part of medical care. Growing chronic disease prevalence and aging populations in the region are expected to drive the regional market growth for peptides. As people age, their bodies become more susceptible to chronic diseases, which require specialized treatments. Additionally, increasing investments in biotechnology and biopharmaceuticals are also anticipated to fuel the regional growth of the market in the forecast period.
Further, the peptide synthesis market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The European region has a large base of pharmaceutical and biotechnology companies that require peptides for manufacturing various drugs and biologics. Moreover, biochemists from the University of Bristol have developed a breakthrough approach for designing and manufacturing peptides. The new approach involves using a combination of machine learning and artificial intelligence to identify peptides that have the desired activity and then using a novel chemical synthesis method to make them. This approach is much faster and more efficient than traditional methods, and it will allow biochemists to create more powerful drugs in a shorter period of time. Furthermore, the presence of government initiatives to promote research and development activities in the region is expected to further propel the growth of the market.
Evonik has released a new peptide to boost cell-culture-based biopharmaceutical productivity. cQrex AC provides cells with a sufficient supply of L-cystine as a chemically defined, highly soluble source of this amino acid. The peptide offers a reliable source of L-cystine, which is an essential component for cell-culture-based biopharmaceuticals. This makes it possible for biopharmaceutical companies to increase their productivity by providing cells with a consistent and sufficient supply of the amino acid.
CordenPharma International company announced a collaboration with PeptiSystems, a Swedish manufacturer of flow-through column-based instruments for research and production of peptide and oligonucleotide therapeutics.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Smruti Ranjan, Rajrani Baghel
Ans: Increasing prevalence of chronic diseases, advancements in biotechnology, and rising demand for personalized medicines are the major factors driving the market growth.
Ans: The market size of peptide synthesis is anticipated to attain a CAGR of ~10.20% over the forecast period, i.e., 2023 – 2035.
Ans: High cost of raw materials, as well as the lack of specialized knowledge in peptide synthesis are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are CordenPharma International, Evonik, CSBio Company Inc., Bachem Holding AG, Biotage, AAPPTec, CEM Corporation, ProteoGenix, GenScript, Thermo Fisher Scientific Inc.
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by product, technology, end user and by region.
Ans: The reagents & consumables segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
